(Q35489187)

English

A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 August 2017

A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease (English)

1 reference

Europe PubMed Central

8 August 2017

phase I clinical trial

0 references

interstitial lung disease

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Dinesh Khanna

1

1 reference

Europe PubMed Central

8 August 2017

Rajeev Saggar

2

1 reference

Europe PubMed Central

8 August 2017

Maureen D Mayes

3

1 reference

Europe PubMed Central

8 August 2017

Fereidoun Abtin

4

1 reference

Europe PubMed Central

8 August 2017

Philip J Clements

5

1 reference

Europe PubMed Central

8 August 2017

Paul Maranian

6

1 reference

Europe PubMed Central

8 August 2017

Shervin Assassi

7

1 reference

Europe PubMed Central

8 August 2017

Rajan Saggar

8

1 reference

Europe PubMed Central

8 August 2017

Ram R Singh

9

1 reference

Europe PubMed Central

8 August 2017

Daniel E Furst

10

1 reference

Europe PubMed Central

8 August 2017

publication date

1 November 2011

1 reference

Europe PubMed Central

8 August 2017

Arthritis & Rheumatology

1 reference

Europe PubMed Central

8 August 2017

63

1 reference

Europe PubMed Central

8 August 2017

11

1 reference

Europe PubMed Central

8 August 2017

3540-3546

1 reference

Europe PubMed Central

8 August 2017

Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205223

12 July 2018

Practical management of tyrosine kinase inhibitor-associated side effects in GIST.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205223

12 July 2018

Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205223

12 July 2018

Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205223

12 July 2018

Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205223

12 July 2018

Role of PDGF in fibrotic diseases and systemic sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205223

12 July 2018

Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast-epithelial cell interactions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205223

12 July 2018

Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205223

12 July 2018

Cyclophosphamide versus placebo in scleroderma lung disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205223

12 July 2018

Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205223

12 July 2018

Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205223

12 July 2018

Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205223

12 July 2018

Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205223

12 July 2018

Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205223

26 September 2018

Imatinib as a novel therapeutic approach for fibrotic disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205223

26 September 2018

Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205223

26 September 2018

Immunohistochemical localization of transforming growth factor-beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3205223

26 September 2018

Preliminary criteria for the classification of systemic sclerosis (scleroderma)

1 reference

https://api.crossref.org/works/10.1002%2FART.30548

21 January 2018

Measurement of patient outcome in arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.30548

21 January 2018

Myofibroblast induction and microvascular alteration in scleroderma lung fibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21769849

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation

1 reference

https://pubmed.ncbi.nlm.nih.gov/21769849

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/ART.30548

1 reference

Europe PubMed Central

8 August 2017

1 reference

Europe PubMed Central

8 August 2017

1 reference

Europe PubMed Central

8 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35489187&oldid=1954552170"